Abstract: The invention relates to a group of synthetic polypeptides, derived from the pre-S1 region of HBV, that efficiently interfere with early steps of an HBV infection. The peptides of the invention can be used in diagnostics for the detection of antigens and/or antibodies.

Abstract: The present invention relates to lipopeptide-based compounds for use in the diagnosis, prevention and/or treatment of a liver disease or condition, preferably liver involved metabolic diseases, as well as in the control or modification of the cholesterol level or cholesterol uptake and, thus, diagnosis, prevention and/or treatment of a cardiovascular disease. The present invention furthermore relates to an in vitro or in vivo assay or method for testing or measuring the NTCP-mediated transport of test compound(s). The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a liver disease or condition, comprising administering a therapeutically effective amount of a lipopeptide-based compound to a patient. The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a cardiovascular disease.

Abstract: The present invention relates to a novel Hepatitis B virus (HBV) and/or Hepatitis D virus (HDV) receptor and its use for the development of cells, cell lines and non-human animals that are susceptible to HBV and/or HDV infection and can be used for immunological studies and/or for the screening of drugs, post-entry restriction factors and host dependency factors. It further relates to the use of the receptor for the identification of compounds useful in the treatment of HBV and/or HDV infection.

Abstract: The invention relates to an electronically commutated electric motor. The electric motor has a stator and a rotor, in particular one formed with permanent magnets. The electric motor has a control unit, which is connected on the output side in particular via a power output stage to the stator and is designed to energize the stator so as to produce a rotating magnetic field. The electric motor has a power output stage with semiconductor switches. The power output stage is connected to the stator via at least one controllable switch disconnector. The control unit is designed to detect a defect of a semiconductor switch depending on a braking torque caused by the defect, in particular a change over time in the braking torque, on a rotor of the electric motor, and to activate the switch disconnector so as to disconnect the defective semiconductor switch from the stator.

Abstract: The present invention relates to hydrophobic modified peptides for the specific delivery of labels to the liver, preferably to hepatocytes, in vitro as well as in vivo. The present invention relates to pharmaceutical compositions comprising said hydrophobic modified peptide(s) and the label(s) to be specifically delivered to the liver. The present invention furthermore relates to the diagnostic use of the inventive hydrophobic modified peptides as well as to a method for the diagnosis of liver diseases or disorders.

Abstract: The invention relates to an electronically commutated electric motor. The electric motor has a stator and a rotor, in particular one formed with permanent magnets. The electric motor has a control unit, which is connected on the output side in particular via a power output stage to the stator and is designed to energize the stator so as to produce a rotating magnetic field. The electric motor has a power output stage with semiconductor switches. The power output stage is connected to the stator via at least one controllable switch disconnector. The control unit is designed to detect a defect of a semiconductor switch depending on a braking torque caused by the defect, in particular a change over time in the braking torque, on a rotor of the electric motor, and to activate the switch disconnector so as to disconnect the defective semiconductor switch from the stator.

Abstract: The present invention relates to hydrophobic modified peptides for the specific delivery of compounds to the liver, preferably to hepatocytes, in vitro as well as in vivo. The present invention relates to pharmaceutical compositions comprising said hydrophobic modified peptide(s) and the compound(s) to be specifically delivered to the liver. The present invention furthermore relates to the use of the inventive hydrophobic modified peptides as well as to a method for the prevention and/or treatment of liver diseases or disorders.

Abstract: The invention relates to a group of synthetic polypeptides, derived from the pre-S1 region of HBV, that efficiently interfere with early steps of an HBV infection. The peptides of the invention can be used in diagnostics for the detection of antigens and/or antibodies.

Abstract: A connecting element between a motor and a control unit includes a flat base plate having electrical bushings and an, in particular centered, opening. The base plate further includes a shaft around the opening. A first seal is provided at the edge of the base plate and a second seal is provided at the upper edge of the shaft.

Abstract: The invention relates to a group of synthetic polypeptides, derived from the pre-S1 region of HBV, that efficiently interfere with early steps of an HBV infection. The peptides of the invention can be used in diagnostics for the detection of antigens and/or antibodies.

Abstract: The invention relates to a group of synthetic polypeptides, derived from the pre-S1 region of HBV, that efficiently interfere with early steps of an HBV infection. The peptides of the invention can be used in diagnostics for the detection of antigens and/or antibodies.

Abstract: The present invention relates to hydrophobic modified preS-derived peptides of hepatitis B virus (HBV) which are versatile vehicles for the specific delivery of compounds to the liver, preferably to hepatocytes, in vitro as well as in vivo. Any kind of compound, but in particular drugs, such as interferons, viral reverse transcriptase inhibitors or core assembly inhibitors, and/or labels can be specifically targeted to the liver and so be enriched in the liver. This liver targeting can further be used for the targeted diagnosis, prevention and/or treatment of liver diseases or disorders, such as hepatitis, malaria, hepatocellular carcinoma (HCC), as well as for the prevention of HAV, HBV, HCV and/or HDV infection. The present invention relates to pharmaceutical compositions comprising said hydrophobic modified preS-derived peptide(s) and the compound(s) to be specifically delivered to the liver.

Abstract: The present invention relates to hydrophobic modified preS-derived peptides of hepatitis B virus (HBV) which are derived from a HBV preS consensus sequence and are N-terminal preferably acylated and optional C-terminal modified. These hydrophobic modified preS-derived peptides of HBV are very effective HBV entry inhibitors as well as HDV entry inhibitors and are, thus, suitable for the inhibition of HBV and/or HDV infection, prevention of primary HBV and/or HDV infection as well as treatment of (chronic) hepatitis B and/or D. The present invention further relates to pharmaceutical and vaccine compositions comprising these hydrophobic modified preS-derived peptides of HBV.

Abstract: The invention relates to a group of synthetic polypeptides, derived from the pre-S 1 region of HBV, that efficiently interfere with early steps of an HBV infection. The peptides of the invention can be used in diagnostics for the detection of antigens and/or antibodies.

Abstract: This invention relates to a group of synthetic polypeptides, derived from the pre-S1 region of HBV, that efficiently interferes with early steps of an HBV infection. The peptides of the invention can be used in diagnostics for the detection of antigens and/or antibodies.

Abstract: A service package application program employing a service activation manager for use with a service control point in an advanced intelligent network is disclosed. The service package application program is employed to provide multiple services to subscribing users. The services are implemented by one or more decision graph nodes stored as a plurality of independent functional blocks. The services are defined by logic maps specifying logically ordered combinations of the decision graph nodes. The service activation manager includes: a subscriber identifier in communication with a subscriber database; a service identifier in communication with a trigger database; an active services list compiler; and a service manager. The subscriber identifier identifies a user associated with a phone call from a received query event message, and cooperates with a subscriber database to develop a subscription services list of phone call services subscribed to by the identified user.

Abstract: A service package application program employing a service activation manager for use with a service control point in an advanced intelligent network is disclosed. The service package application program is employed to provide multiple services to subscribing users. The services are implemented by one or more decision graph nodes stored as a plurality of independent functional blocks. The services are defined by logic maps specifying logically ordered combinations of the decision graph nodes. The service activation manager includes: a subscriber identifier in communication with a subscriber database; a service identifier in communication with a trigger database; an active services list compiler; and a service manager.